Prevalencia y la patogénesis de la trombofilia de origen genético en mujeres embarazadas.
Palabras clave:
Prevalencia, trombofilia, genética, embarazo.Resumen
Las trombofilias son definidas como el estado protrombótico y de hipercoagulación instaurado tras la alteración de factores relacionados con la coagulación que, en caso de presentarse de forma simultánea en el embarazo, que se caracteriza por su estado de hipercoagulabilidad fisiológico, aumenta el riesgo de eventos protrombóticos, promoviendo la susceptibilidad a pérdida gestacional, muerte materna, preeclampsia y restricción del crecimiento intrauterino. El objetivo de este manuscrito es describir la prevalencia y fisiopatología asociadas a factores genéticos de la trombofilia en mujeres embarazadas. En cuanto a metodología, se trata de una revisión bibliográfica a través de las bases de datos como MEDLINE, Embase y Web of Science de artículos originales y reportes de casos en inglés y español publicados en los últimos 15 años. Como resultado se obtuvo que la mayor prevalencia de trombofilias de origen genético está asociadas a presentar el Factor V Leiden, seguida de la deficiencia de la proteína S. A pesar de los avances en la comprensión de las trombofilias, aún existe una falta de estudios sobre su prevalencia en diversas poblaciones, como Latinoamérica.
Descargas
Referencias
1. Gutiérrez-Castañeda MR, Font-López KC. Trombofilias y embarazo: incidencia, factores de riesgo y resultados perinatales. Ginecol. obstet. Méx. [revista en la Internet]. 2017; 85( 10 ): 676-684.
1. Website [Internet]. Available from: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0300-90412017001000676&lng=es. https://doi.org/10.24245/gom.v85i10.1530
2. Arachchillage DRJ, Makris M. Inherited Thrombophilia and Pregnancy Complications: Should We Test? Semin Thromb Hemost. 2019 Feb;45(1):50–60.
3. Reyes Utiérrez-Tous M. Trombofilia, ¿cuándo, qué pruebas y a quién? Sem Fund Es Reumatol. 2005 Dec;6(4):133–43.
4. Erez O. Disseminated intravascular coagulation in pregnancy – Clinical phenotypes and diagnostic scores. Thrombosis Research. 2017 Mar 1;151:S56–60.
5. Elgendy IY, Fogerty A, Blanco-Molina Á, Rosa V, Schellong S, Skride A, et al. Clinical Characteristics and Outcomes of Women Presenting with Venous Thromboembolism during Pregnancy and Postpartum Period: Findings from the RIETE Registry. Thromb Haemost. 2020 Oct;120(10):1454–62.
6. Zheng L, Ge R, Weng X, Lin L. Predictive Value of Serum Immune-Inflammatory Markers for Adverse Pregnancy Outcomes in Pregnant Women with Thrombophilia: A Retrospective Cohort Study. J Inflamm Res. 2024 Sep 5;17:6083–91.
7. Ahangari N, Doosti M, Mousavifar N, Attaran M, Shahrokhzadeh S, Memarpour S, et al. Hereditary thrombophilia genetic variants in recurrent pregnancy loss. Arch Gynecol Obstet. 2019 Sep;300(3):777–82.
8. Pritchard AM, Hendrix PW, Paidas MJ. Hereditary Thrombophilia and Recurrent Pregnancy Loss. Clin Obstet Gynecol. 2016 Sep;59(3):487–97.
9. Gierula M, Ahnström J. Anticoagulant protein S-New insights on interactions and functions. J Thromb Haemost. 2020 Nov;18(11):2801–11.
10. Gerhardt A, Scharf RE, Greer IA, Zotz RB. Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. Blood. 2016 Nov 10;128(19):2343–9.
11. Lykke JA, Bare LA, Olsen J, Lagier R, Arellano AR, Tong C, et al. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost. 2012 Jul;10(7):1320–5.
12. Campello E, Spiezia L, Adamo A, Simioni P. Thrombophilia, risk factors and prevention. Expert Rev Hematol. 2019 Mar;12(3):147–58.
13. Kyrle PA, Mannhalter C, Béguin S, Stümpflen A, Hirschl M, Weltermann A, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1287–91.
14. Kujovich JL. Prothrombin Thrombophilia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 2006.
15. Rezaie AR, Giri H. Anticoagulant and signaling functions of antithrombin. J Thromb Haemost. 2020 Dec;18(12):3142–53.
16. Hart C, Rott H, Heimerl S, Linnemann B. Management of Antithrombin Deficiency in Pregnancy. Hamostaseologie. 2022 Oct;42(5):320–9.
17. Arachchillage DRJ, Makris M. Erratum: Inherited Thrombophilia and Pregnancy Complications: Should We Test? Semin Thromb Hemost. 2019 Feb;45(1):e1.
18. Khider L, Gendron N, Mauge L. Inherited thrombophilia in the era of direct oral anticoagulants. Int J Mol Sci. 2022 Feb 5;23(3):1821.
19. Dahlbäck B. Vitamin K-Dependent Protein S: Beyond the Protein C Pathway. Semin Thromb Hemost. 2018 Mar;44(2):176–84.
20. ten Kate MK, van der Meer J. Protein S deficiency: a clinical perspective. Haemophilia. 2008 Nov;14(6):1222–8.
21. Burstyn-Cohen T, Heeb MJ, Lemke G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest. 2009 Oct;119(10):2942–53.
22. Tse J, Gongolli J, Prahlow JA. Hereditary thrombophilia as a possible risk factor for severe disease in COVID-19: a case series. Forensic Science, Medicine and Pathology. 2024 Sep 27;1–7.
23. Hennessey-Calderón, Diana Carolina, Natalia Remolina-Murillo, and Daniel Alejandro Queremel-Milani. “Trombofilia por hiperhomocisteinemia secundaria a mutación del gen MTHFR.” Revista de Hematología 22.1 (2021): 56-61
24. Khalife S, Geitani R. Association of Inherited Thrombophilia with Recurrent Pregnancy Loss in A Population of Lebanese Women: A Case Control Study. Int J Fertil Steril. 2022 Aug 21;16(3):247–51.
25. Schmaier AH. Histidine-rich glycoprotein: antithrombosis without bleeding. Blood Adv. 2023 Sep 26;7(18):5649–50.
26. Malik RA, Zhou J, Fredenburgh JC, Truong TK, Crosby JR, Revenko AS, et al. Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. Blood Adv. 2021 Sep 28;5(18):3540–51.
27. Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009 Oct 22;361(17):1671–5.
28. Chuliber, Fernando Andrés, et al. “Déficit adquirido de factor XIII:: manifestaciones hemorrágicas en pacientes internados.” Revista Hematología 23.2 (2019): 38-48.
29. García-Santibáñez, Rocío, et al. “Activador del Plasminógeno tisular, realidad actual. Estudio transversal retrospectivo entre los años 2007-2009 en el Hospital Regional Dr. Teodoro Maldonado Carbo.” Rev Ecuat Neurol 20.1-3 (2011): 20-26.
30. Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous thromboembolism. Nature Reviews Cardiology. 2014 Jan 14;11(3):140–56.
31. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295–306.
32. Noordermeer T, Chemlal S, Jansma JJ, van der Vegte V, Schutgens REG, Limper M, et al. Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C. J Thromb Haemost. 2023 Sep;21(9):2509–18.
33. Ortel TL. Antiphospholipid syndrome: Laboratory testing and diagnostic strategies. American journal of hematology. 2012 Mar 14;87(S1):S75–81.
34. Berkman SA, Song SS. Ischemic Stroke in the Young. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211002274.
35. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry.” J Autoimmun. 2009 Mar 26;32(3-4):240–5.
36. Kadhim Al-Banaa, Emma Herrman, Bana Antonios, Hycienth Ahaneku, Shiva Shrotriya, Can Wang, Daniel E Ezekwudo, Ishmael Jaiyesimi. Assessing the Rate of Compliance with the Revised Sapporo/Sydney Criteria in Diagnosing Antiphospholipid Syndrome: A Multicenter Retrospective Analysis. Blood. 2022 Nov 2;140(Supplement 1):2795–6.
37. Bitsadze V, Khizroeva J, Lazarchuk A, Salnikova P, Yagubova F, Tretyakova M, et al. Pediatric antiphospholipid syndrome: is it the same as an adult? J Matern Fetal Neonatal Med. 2024 Dec;37(1):2390637.
38. Jakobsen IM, Helmig RB, Stengaard-Pedersen K. Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990-2010. Scand J Rheumatol. 2015 Jun 19;44(5):377–84.
39. Casares-Marfil D, Martínez-Bueno M, Borghi MO, Pons-Estel G, PRECISESADS Clinical Consortium, Reales G, et al. A Genome-Wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome. Arthritis Rheumatol. 2024 Nov;76(11):1623–34.
40. Dautaj A, Krasi G, Bushati V, Precone V, Gheza M, Fioretti F, et al. Hereditary thrombophilia. Acta Biomed. 2019 Sep 30;90(10-S):44–6.
41. Hristova M. Overcoming Recurrent Miscarriages in a 35-Year-Old Female With Thrombophilia. Cureus. 2024 Jun;16(6):e62870.
42. Villamizar Olarte, Diana Marcela, and Luis Andrés Dulcey-Sarmiento. “Condiciones trombofilicas y su riesgo en una cohorte latinoamericana de gestantes, estudio observacional descriptivo.” Revista de Obstetricia y Ginecología de Venezuela 84.1 (2024): 33-41.
43. Younis M, Ali MAM, Ghareeb DA, Youssef R, Fathy SA. Maternal Thrombophilic and Hypofibrinolytic Genetic Variants in Idiopathic Recurrent Pregnancy Loss: a Continuing Mystery. Reproductive Sciences. 2022 Aug 15;30(2):656–66.
44. Nahas R, Saliba W, Elias A, Elias M. The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages. Clin Appl Thromb Hemost. 2018 Jan;24(1):122–8.
45. Nassour-Mokhtari I, Loukidi B, Moussouni A, Bettioui R, Benhabib R, Merzouk H, et al. Inherited thrombophilia and recurrent pregnancy loss: a single-center case-control study in North-Western Algeria. Egyptian Journal of Medical Human Genetics. 2020 Aug 17;21(1):1–7.
46. Cernera G, Liguori R, Bruzzese D, Castaldo G, De Placido G, Conforti A, et al. The relevance of prothrombotic genetic variants in women who experienced pregnancy loss or embryo implantation failure: A retrospective analysis of 1922 cases. Int J Gynaecol Obstet. 2024 Apr;165(1):148–54.
47. Samfireag, Miruna, et al. “Assessment of the Particularities of Thrombophilia in the Management of Pregnant Women in the Western Part of Romania.” Medicina 59.5 (2023): 851.
48. Kashifard M, Basirat Z, Ramezani F, Ghofrani F, Golsorkhtabaramiri M. Combined Parental Thrombophilia Gene Mutation Defects in Couples with Repeated Pregnancy Loss. J Hum Reprod Sci. 2023 Dec 29;16(4):352–7.
49. Ginecología y Obstetricia de México [Internet]. Vol. 85. Nieto Editores; 2021. Available from: https://ginecologiayobstetricia.org.mx/articulo/h5strongtrombofilias-y-embarazo-incidencia-factores-de-riesgo-y-resultados-perinatalesstrongh5-h6strongthrombophilia-and-pregnancy-incidence-risk-factors-and-perinatal-resultsstrongh6
50. Inherited thrombophilia and pregnancy loss. Study of an Argentinian cohort. Medicina Clínica (English Edition). 2019 Apr 5;152(7):249–54.
51. Yang B, Liu Y, Li Y, Fan S, Zhi X, Lu X, et al. Geographical distribution of MTHFR C677T, A1298C and MTRR A66G gene polymorphisms in China: findings from 15357 adults of Han nationality. PLoS One. 2013 Mar 5;8(3):e57917.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 Nicoll Valentina Caamaño-Sierra, Estefania Bula-Escarria
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
